Advanced Search

Journal of Traditional Chinese Medicine >

2023 , Vol. 43 >Issue 6: 1092 - 1102

DOI: https://doi.org/10.19852/j.cnki.jtcm.2023.06.004

Research Articles

Hepatic transcriptome delineates the therapeutic effects of Sanren Tang (三仁汤) on high-fat diet-induced non-alcoholic fatty liver disease

  • Yixiao YIN ,
  • Hao TANG ,
  • Yi FANG ,
  • Wei LIU ,
  • Jun WANG ,
  • Yiyang HU ,
  • Jinghua PENG
Expand
  • 1 Institute of Liver diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
    2 Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education, Shanghai 201203, China
    3 Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
    4 Institute of Clinical Pharmacology, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
    5 Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education, Shanghai 201203, China
    6 Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China

Received date: 2022-09-11

  Accepted date: 2022-12-25

  Online published: 2023-11-01

Supported by

Science and Technology Commission Shanghai Municipality: Exploring the Mechanism of Qushi Huayu Formula in Treating Non-alcoholic Fatty Liver Disease from the Perspective of Intestinal Barrier Function(17PJ1408900);Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine: “Si Ming” Scholar(SGXZ-201911)

Fold

Abstract

OBJECTIVE: To evaluate the effects of Sanren Tang (SRT, 三仁汤) on a high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) in mice and to investigate the hepatic transcriptome regulated by SRT.
METHODS: The primary SRT components were identified using ultra-high-performance liquid chromatography-high-resolution accurate mass spectrometry. The SRT-induced pharmacological effects on HFD-induced NAFLD were evaluated in mice for 16 weeks. Obeticholic acid was used as a control drug. Body weight, food intake, and homeostatic model assessment for insulin resistance (HOMA-IR) index were analysed. Hepatic histological changes were observed in haematoxylin and eosin-stained sections and quantified using the NAFLD activity score (NAS). Serum alanine aminotransferase (ALT) and hepatic triglyceride (TG) levels were measured. Lipids in hepatocytes were visualised by Oil red staining. RNA-sequencing was performed to determine the transcriptome profile of the liver tissue. The differentially expressed genes were validated using real-time polymerase chain reaction and Western blotting.
RESULTS: Four principal compounds were identified in the SRT: adenosine, amygdalin, luteoloside, and magnolol. SRT ameliorated hepatic histology and lipid deposition in the NAFLD mice, and decreased HOMA-IR, NAS and ALT, and hepatic TG levels. Hepatic transcriptome analysis revealed 232 HFD-regulated genes that were reversed by SRT simultaneously. Retinol metabolism, cytokine-cytokine receptor interaction, and peroxisome proliferator-activated receptor (PPAR) γ signalling were the top three SRT-regulated pathways in NAFLD.
CONCLUSIONS: SRT significantly ameliorated HFD-induced NAFLD, which was correlated with the regulation of genes enriched in the retinol metabolism, cytokine-cytokine receptor interaction, and PPARγ signalling pathways.

Key words： non-alcoholic fatty liver disease; vitamin A metabolism; PPAR gamma; cytokine-cytokine receptor interaction; Sanren Tang

Cite this article

Yixiao YIN , Hao TANG , Yi FANG , Wei LIU , Jun WANG , Yiyang HU , Jinghua PENG . Hepatic transcriptome delineates the therapeutic effects of Sanren Tang (三仁汤) on high-fat diet-induced non-alcoholic fatty liver disease[J]. Journal of Traditional Chinese Medicine, 2023 , 43(6) : 1092 -1102 . DOI: 10.19852/j.cnki.jtcm.2023.06.004

References

1. Francque SM, Marchesini G, Kautz A, et al. Non-alcoholic fatty liver disease: apatient guideline. JHEP Rep 2021; 3: 100322.
2. Zhang S, Li J. Expert consensus on TCM diagnosis and treatment of nonalcoholic fatty liver disease (2017). Lin Chuang GanDan Bing Za Zhi 2017; 33: 2270-4.
3. Liu P. Clinical observation of Jiangzhi Sanren decoction in the treatment of nonalcoholic steatohepatitis with damp-heat intrinsic type. Shenyang: Liaoning Uniersity of Traditional Chinese Medicine, 2019: 1-37.
4. The National Administration of Traditional Chinese Medicine and the National Health Commission of People's Republic of China. Notification of the National Administration of Traditional Chinese Medicine and the National Health Commission of People's Republic of China on Printing and distributing the Management Standards of Chinese Medicine decocting rooms in medical institutions. Gazette of the National Health Commission of People's Republic of China 2009; 6: 29-31.
5. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
6. Leng J, Huang F, Hai Y, et al. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. Phytomedicine 2020; 66: 153135.
7. Rodrigues PM, Afonso MB, Sim?o AL, et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 2017; 8: e2748.
8. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
9. Vogeser M, Konig D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 2007; 40: 964-8.
10. Peng JH, Leng J, Tian HJ, et al. Geniposide and chlorogenic acid combination ameliorates non-alcoholic steatohepatitis involving the protection on the gut barrier function in mouse induced by high-fat diet. Front Pharmacol 2018; 9: 1399.
11. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 2014; 30: 2114-20.
12. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods 2015; 12: 357-60.
13. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-5.
14. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166-9.
15. Tong J, Han CJ, Zhang JZ, et al. Hepatic interferon regulatory factor 6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing peroxisome proliferator-activated receptor gamma in mice. Hepatology 2019; 69: 2471-88.
16. Blomhoff R, Green MH, Green JB, Berg T, Norum KR. Vitamin A metabolism: new perspectives on absorption, transport, and storage. Physiol Rev 1991; 71: 951-90.
17. Senoo H, Mezaki Y, Fujiwara M. The stellate cell system (vitamin A-storing cell system). Anat Sci Int 2017; 92: 387-455.
18. Coelho JM, Cansancao K, Perez RM, et al. Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study. PeerJ 2020; 8: e9838.
19. Jeon D, Son M, Shim J. Dynamics of serum retinol and alpha-tocopherol levels according to non-alcoholic fatty liver disease status. Nutrients 2021; 13: 1720.
20. Ashla AA, Hoshikawa Y, Tsuchiya H, et al. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010; 40: 594-604.
21. Nakano M, Kelly EJ, Wiek C, Hanenberg H, Rettie AE. CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of omega-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant. Mol Pharmacol 2012; 82: 679-86.
22. Jarrar YB, Jarrar Q, Abed A, Abu-Shalhoob M. Effects of nonsteroidal anti-inflammatory drugs on the expression of arachidonic acid-metabolizing Cyp450 genes in mouse hearts, kidneys and livers. Prostaglandins Other Lipid Mediat 2019; 141: 14-21.
23. Ito O, Nakamura Y, Tan L, et al. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human. Mol Cell Biochem 2006; 284: 141-8.
24. Roh YS, Seki E. Chemokines and Chemokine Receptors in the Development of NAFLD. Adv Exp Med Biol 2018; 1061: 45-53.
25. Mullen RD, Ontiveros AE, Moses MM, Behringer RR. AMH and AMHR2 mutations: aspectrum of reproductive phenotypes across vertebrate species. Dev Biol 2019; 455: 1-9.
26. Deng C, Lin YX, Qi XK, et al. TNFRSF19 Inhibits TGFbeta signaling through Interaction with TGFbeta receptor type I to promote tumorigenesis. Cancer Res 2018; 78: 3469-83.
27. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-15.
28. Obstfeld AE, Sugaru E, Thearle M, et al. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 2010; 59: 916-25.
29. Ali AA, Fouda A, Abdelaziz ES, Abdelkawy K, Ahmed MH. The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations. Eur J Gastroenterol Hepatol 2021; 33: e954-60.
30. Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52: 1549-53.
31. Yang L, Miura K, Zhang B, et al. TRIF differentially regulates hepatic steatosis and inflammation/fibrosis in mice. Cell Mol Gastroenterol Hepatol 2017; 3: 469-83.
32. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-alpha. Future Cardiol 2017; 13: 259-78.
33. Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-beta/delta and PPAR-gamma. Future Cardiol 2017; 13: 279-96.
34. Matsusue K, Haluzik M, Lambert G, et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003; 111: 737-47.
35. Houten SM, Denis S, Argmann CA, et al. Peroxisomal L-bifunctional enzyme (Ehhadh) is essential for the production of medium-chain dicarboxylic acids. J Lipid Res 2012; 53: 1296-303.
36. Abdollahi H, Zamanian Azodi M, Hatami B. Protein interaction mapping interpretation of none alcoholic fatty liver disease model of rats after fat diet feeding. Gastroenterol Hepatol Bed Bench 2017; 10: S146-53.
37. Schwarz M, Russell DW, Dietschy JM, Turley SD. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J Lipid Res 1998; 39: 1833-43.
38. Duan Y, Chen Y, Hu W, et al. Peroxisome Proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem 2012; 287: 23667-77.
39. Inoue M, Ohtake T, Motomura W, et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 2005; 336: 215-22.
40. Benton CR, Koonen DP, Calles-Escandon J, et al. Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. J Physiol 2006; 573: 199-210.
41. Gao M, Ma Y, Alsaggar M, Liu D. Dual outcomes of rosiglitazone treatment on fatty liver. AAPS J 2016; 18: 1023-31.
42. Rada P, Gonzalez-Rodriguez A, Garcia-Monzon C, Valverde AM. Understanding lipotoxicity in NAFLD pathogenesis: is CD36a key driver? Cell Death Dis 2020; 11: 802.
43. Miquilena-Colina ME, Lima-Cabello E, Sanchez-Campos S, et al. Hepatic fatty acid translocase CD36upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011; 60: 1394-402.
44. Kawanishi N, Mizokami T, Yada K, Suzuki K. Exercise training suppresses scavenger receptor CD36 expression in kupffer cells of nonalcoholic steatohepatitis model mice. Physiol Rep 2018; 6: e13902.
45. Koonen DP, Jacobs RL, Febbraio M, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 2007; 56: 2863-71.
46. Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 2016; 157: 570-85.
47. Kuo NC, Huang SY, Yang CY, Shen HH, Lee YM. Involvement of HO-1 and autophagy in the protective effect of magnolol in hepatic steatosis-induced NLRP3 inflammasome activation in vivo and in vitro. Antioxidants (Basel) 2020; 9.
48. Lee YS, Choi SS, Yonezawa T, et al. Honokiol, magnolol, and a combination of both compounds improve glucose metabolism in high-fat diet-induced obese mice. Food Science and Biotechnology 2015; 24: 8.
49. Xiao Z, Ji Q, Fu YD, et al. Amygdalin ameliorates liver fibrosis through inhibiting activation of TGF-beta/smad signaling. Chin J Integr Med 2023; 29: 316-24.
50. Elsaed WM. Amygdalin (Vitamin B17) pretreatment attenuates experimentally induced acute autoimmune hepatitis through reduction of CD4+ cell infiltration. Ann Anat 2019; 224: 124-32.
51. Tang F, Fan K, Wang K, Bian C. Amygdalin attenuates acute liver injury induced by D-galactosamine and lipopolysaccharide by regulating the NLRP3, NF-kappaB and Nrf2/NQO1 signalling pathways. Biomed Pharmacother 2019; 111: 527-36.
52. Sun J, Wang Z, Chen L, Sun G. Hypolipidemic effects and preliminary mechanism of chrysanthemum flavonoids, its main components luteolin and luteoloside in hyperlipidemia rats. Antioxidants (Basel) 2021; 10: 1309.
53. Jain S, Jacobson KA. Purinergic signaling in liver pathophysiology. Front Endocrinol (Lausanne) 2021; 12: 718429.
Options
Outlines

/

〈 〉